

**Date:** May 14, 2026

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

**Sub.: Submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants, for the quarter ended on March 31, 2026**

Dear Sir/Madam,

Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through preferential issue of 11,70,000 convertible equity warrants by the Company, for the quarter ended March 31, 2026.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of the funds raised through preferential issue of convertible equity warrants, for the abovementioned period, for the objects stated in the explanatory statement to the Notice of the Extra-ordinary General Meeting held on January 31, 2026.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on May 14, 2026.

This intimation is also being uploaded on the website of the Company i.e. [www.senorespharma.com](http://www.senorespharma.com).

You are requested to take the same on record.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Enclosure:** As above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

**STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED MARCH 31, 2026**

<b>Name of listed entity</b>	Senores Pharmaceuticals Limited
<b>Mode of Fund Raising</b>	Preferential Issue of 11,70,000 Convertible Equity Warrants each convertible into one Equity Share of face value ₹10/- (Rupees Ten only) each, at an exercise price of ₹ 812/- (Rupees Eight Hundred and Twelve only) per Warrant
<b>Date of Raising Funds</b>	March 28, 2026
<b>Amount Raised</b>	Rs. 95,00,40,000
<b>Report filed for Quarter ended</b>	March 31, 2026
<b>Monitoring Agency</b>	Not Applicable
<b>Monitoring Agency Name, if applicable</b>	Not Applicable
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation / Variation</b>	Not Applicable
<b>Comments of the Audit Committee after review</b>	No comments
<b>Comments of the auditors, if any</b>	No comments

<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>						
<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified Allocation, if any</b>	<b>Funds Utilized</b>	<b>Amount of Deviation/ Variation for the quarter according to applicable object</b>	<b>Remarks, if any</b>
Funding the working capital requirements of our Company	Not Applicable	31,25,30,000	Not Applicable	2,50,00,000	No deviation	-

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

Funding the product development expenditure for the Company	Not Applicable	25,00,00,000	Not Applicable	Nil	No deviation	-
Investment in our subsidiaries, by way of loan, to fund their working capital requirements	Not Applicable	15,00,00,000	Not Applicable	2,50,00,000	No deviation	-
General Corporate Purpose	Not Applicable	23,75,10,000	Not Applicable	Nil	No deviation	-
<b>Total</b>		<b>95,00,40,000</b>		<b>5,00,00,000</b>		

**Deviation or variation could mean:**

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**

Company Secretary and Compliance Officer

ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263